LL-37 is a human antimicrobial peptide involved in host defense and immune signaling. Researchers have tested a synthetic version for wound healing, but that does not make it a proven injection treatment for chronic infections or a general immune booster. The larger randomized venous-ulcer trial did not find a significant healing benefit across its full study population. [1] [2]
LL-37 can defend tissue in one setting and contribute to inflammation or unwanted cell growth in another. “Antimicrobial” describes an observed activity, not a guarantee that treatment helps patients.
What is LL-37?
LL-37 is a mature, 37-amino-acid peptide produced from the human cathelicidin precursor hCAP18. Researchers first isolated it from granulocytes, a type of white blood cell, and demonstrated antibacterial activity in laboratory tests. [1]
It is often called a host-defense peptide. That description is broader than “natural antibiotic”: researchers study its effects on microbes, inflammatory signaling and tissue responses. The LL-37 already present in the body and a manufactured product supplied from outside it are not interchangeable safety questions.
- Identity: human cathelicidin antimicrobial peptide.
- Clinical research: topical treatment of difficult-to-heal venous leg ulcers.
- Main limitation: promising early findings were not confirmed across the larger trial’s full population.
- Safety gap: topical trial experience does not establish a safe injection dose or long-term systemic use. [2] [3]
Related dosage pages: For vial-specific concentration, reconstitution, and measurement examples, see LL-37 (5 mg Vial) Dosage Protocol. Each linked protocol remains a separate reference because vial strength changes concentration and syringe-unit calculations.
LL-37 benefits: what has actually been tested?
The strongest way to assess a claim is to identify the intervention and outcome. Bacterial growth in a laboratory dish, a wound closing in a patient and a person reporting more energy are not the same result.
| Research question | Evidence | What readers can conclude |
|---|---|---|
| Can it act against microbes? | Laboratory antibacterial assays and studies comparing LL-37 with modified fragments. | Biological activity is documented; this does not establish a treatment for a person’s infection. [1] [4] |
| Can topical LL-37 improve venous-ulcer healing? | A 34-person pilot reported encouraging findings at lower concentrations. A later 148-person trial found no significant overall healing advantage. | Clinical benefit remains uncertain. The larger trial must not be omitted from the story. [5] [2] |
| Does it always reduce inflammation? | Experiments linked LL-37/self-DNA complexes to inflammatory signaling in psoriasis research. | Its immune effects depend on context; “immune boosting” is too simple. [6] |
| Is systemic use established as safe? | FDA identifies substantial safety uncertainties for compounded LL-37. | There is no dependable general side-effect rate or self-injection regimen in this evidence. [3] |
The wound-healing studies, in order
The 2014 pilot enrolled 34 people with hard-to-heal venous leg ulcers. It tested topical LL-37 twice weekly over four weeks. Lower concentrations produced encouraging healing measures; the highest concentration did not improve healing compared with placebo. This was an early dose-finding signal, not the final word on effectiveness. [5]
The 2021 HEAL LL-37 trial paired topical treatment with compression therapy. A post hoc analysis suggested a possible benefit for larger ulcers, despite the negative overall result. That subgroup signal needs a dedicated trial, not promotion as a confirmed benefit. Developer employees were among the authors. [2]
Neither trial tested routine subcutaneous injections for recovery, Lyme disease or generalized “immune support.” Changing the route changes the question; a topical concentration cannot simply be converted into an injectable dose.
How do its antimicrobial effects work?
LL-37 and related fragments have shown activity against microorganisms in controlled experiments. In a 2006 study, investigators compared LL-37 with shorter synthetic peptides and examined antimicrobial activity, binding to bacterial lipopolysaccharide and toxicity to cells. One fragment retained useful experimental activity with less toxicity in the assays. [4]
That helps explain why scientists investigate LL-37 derivatives rather than assuming the original molecule is already an ideal medicine. A candidate needs to reach the relevant tissue, remain active and avoid damaging host cells. Laboratory potency is only one part of that problem.
Does that mean it treats Lyme disease or other infections?
No such conclusion follows from these sources. An antimicrobial assay does not show that a product clears an infection in people, reaches the organism at a tolerable exposure or improves patient outcomes. The human trials summarized here concern topical wound care, not a validated Lyme-treatment protocol.
If a treatment claim mentions “biofilms,” ask for the actual human study, the organism, the route and the measured outcome. Do not replace prescribed infection treatment with an experimental product based on a mechanism or testimonial. A clinician needs to establish what is causing the symptoms first.
Why can LL-37 have opposite-looking effects?
In a psoriasis study, LL-37 helped self-DNA stimulate plasmacytoid dendritic cells through an immune-sensing pathway, promoting interferon signaling. This helps explain a disease mechanism. It does not show that giving LL-37 treats psoriasis, nor does it prove that every exposure causes it. [6]
Cancer research also argues against describing the peptide as universally protective. A lung-cancer study found increased growth in cell experiments and a mouse tumor model associated with LL-37. Those are preclinical findings, not a measured cancer risk in people receiving a particular product. They are still important counterevidence to broad claims of harmlessness. [7]
Location, concentration, interacting molecules and the type of cell all matter. “The body makes it” answers an identity question; it does not establish what happens when additional peptide is introduced elsewhere.
LL-37 side effects and safety concerns
The wound trials reported tolerability in their specific topical settings. That is not a blanket safety assessment for other formulations, routes or populations. Small studies also cannot reliably rule out uncommon problems. [5] [2]
FDA’s current compounding safety information highlights potential immune reactions, peptide impurities and difficulties characterizing the active ingredient. It also identifies nonclinical concerns involving male reproduction and tumor-promoting effects in some tissues. These are reasons for caution, not established frequencies of those outcomes in humans. [3]
It is not possible to give a reliable “most users experience only…” list for unapproved LL-37 injections from this evidence. If symptoms develop after a product, do not label them detoxification or assume worsening means it is working. Seek medical advice; trouble breathing, fainting or severe swelling warrants urgent care.
Is there an established LL-37 dosage?
The sources here do not establish a self-directed injection dose, cycle or stacking plan. Topical wound-study concentrations answer a different research question. Converting milligrams to syringe markings is arithmetic, not clinical validation.
Does compounding mean FDA approval?
No. FDA explains that compounded drugs are not FDA-approved and are not the same as approved generic medicines. Poor preparation can introduce contamination or incorrect ingredient amounts. Being available through a supplier or discussed by a clinic does not resolve those quality and evidence questions. [8]
Check an LL-37 claim in under a minute
- Is the paper about LL-37 itself, a fragment or a modified derivative?
- Were people treated, or were cells, microbes or animals studied?
- Does the claimed route match the study?
- Does the summary include the larger negative wound trial?
- Are adverse effects and uncertainty described as clearly as the claimed benefit?
If the answer is unclear, follow the reference before sharing the claim.
The takeaway
LL-37 is an important research molecule, not a simple all-purpose immune booster. Its antimicrobial biology is established, but clinical benefit is a separate question. The mixed wound-healing findings and context-dependent immune effects deserve at least as much attention as the early positive results. Discuss persistent wounds or suspected infection with a qualified healthcare professional rather than relying on an experimental peptide protocol.
Related dosage protocols and research
Explore related research, dosage references and guides below. Vial strengths have separate references because concentration and syringe-unit calculations differ. A comparison does not mean the compounds are interchangeable.
Matching dosage protocols
Further research context
References
- Gudmundsson GH et al. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. European Journal of Biochemistry. 1996.
- Mahlapuu M et al. Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: a randomized placebo-controlled trial. Wound Repair and Regeneration. 2021.
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Cathelicidin LL-37 entry; accessed October 6, 2026.
- Sigurdardottir T et al. In silico identification and biological evaluation of antimicrobial peptides based on human cathelicidin LL-37. Antimicrobial Agents and Chemotherapy. 2006.
- Grönberg A et al. Topical LL-37 in hard-to-heal venous leg ulcers: randomized pilot trial. Wound Repair and Regeneration. 2014.
- Lande R et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007.
- von Haussen J et al. The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer. 2008.
- US Food and Drug Administration. Compounding and the FDA: questions and answers.